Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial

Hyung Duk Kim; Ji-Yeun Chang; Byung Ha Chung; Chan-Duck Kim; Sang-Ho Lee; Yeong Hoon Kim; Chul Woo Yang

doi:10.12659/AOT.927984

22 January 2021: Original Paper

Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial

Hyung Duk Kim ^1BEF , Ji-Yeun Chang ^1CDE , Byung Ha Chung ^1AB , Chan-Duck Kim ^2B , Sang-Ho Lee ^3B , Yeong Hoon Kim ^4B , Chul Woo Yang ^1ADG*

DOI: 10.12659/AOT.927984

Ann Transplant 2021; 26:e927984

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Supplementary Table 1 Inclusion and exclusion criteria.

MDRD – modification of diet in renal disease; eGFR – estimated glomerular filtration rate; PTDM – post-transplantation diabetes mellitus; PRA – panel-reactive antibody.

Back to the Article

Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial

Your Privacy